Bryan Jones - 15 Oct 2025 Form 4 Insider Report for Aardvark Therapeutics, Inc. (AARD)

Reporting relationship: Chief Operating Officer
Issuer ticker: AARD
Reported as of: 15 Oct 2025
Net transaction value: +$5,300
SEC form: 4
Accepted by SEC: 16 Oct 2025, 18:12:32 UTC
Prior SEC filing: 13 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Nelson Sun, as Attorney-in-Fact

Key filing fact

Bryan Jones filed Form 4 for Aardvark Therapeutics, Inc. (AARD) on 16 Oct 2025.

Key facts

This page summarizes Bryan Jones's Form 4 filing for Aardvark Therapeutics, Inc. (AARD).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Oct 2025, 18:12.

Change

Previous filing in this sequence was filed on 13 Jun 2025.
Current net transaction value: +$5,300.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002045615 Primary reporting owner

Jones Bryan

Relationship: Chief Operating Officer
Address: C/O AARDVARK THERAPEUTICS, INC., 4370 LA JOLLA VILLAGE DRIVE, SUITE 1050, SAN DIEGO
Signature: /s/ Nelson Sun, as Attorney-in-Fact
Signature date: 16 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AARD transaction

Common Stock

Options Exercise

Transaction value: $5,300
Shares: +1,250
Change %
Price: $4.24
Shares after: 1,250
Date: 15 Oct 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AARD transaction Derivative

Stock option (right to buy)

Options Exercise

Transaction value: $0
Shares: -1,250
Change %: -3%
Price: $0.000000
Shares after: 40,052
Date: 15 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,250
Exercise price: $4.24
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/48th of the original number of shares subject to the option vested on July 27, 2024, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.